Akums Drugs & Pharmaceuticals has entered into an agreement with one of Leading Global Pharma Company for manufacture and supply of selected pharmaceutical formulations in European Market. Akums group will manufacture and supply multiple SKUs of Oral Liquid Formulation to be marketed in multiple European countries by the Company.
This is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026. Akums already has 2 of its sites (Injectable and Oral Solids) approved by European Regulators. The composite value of the agreement is around Rs 1,760 crore.
Akums group, against this agreement, will receive an upfront payment for product development and site approval from European authorities. The project has been secured with an upfront payment of Rs 880 crore.
Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1735.45 |
Dr. Reddys Lab | 1144.05 |
Cipla | 1441.70 |
Lupin | 2026.50 |
Zydus Lifesciences | 885.70 |
View more.. |